Stockscreener 앱 받기
6.76
0.44%
-0.03
시간 외 거래:
6.76
전일 마감가:
$6.79
열려 있는:
$6.77
하루 거래량:
3.93M
Relative Volume:
0.80
시가총액:
$2.08B
수익:
$493.67M
순이익/손실:
$-104.69M
주가수익비율:
-19.88
EPS:
-0.34
순현금흐름:
$-31.51M
1주 성능:
+6.96%
1개월 성능:
+8.68%
6개월 성능:
-29.95%
1년 성능:
-40.28%
1일 변동 폭
$6.685
$6.845
1주일 범위
$6.28
$7.065
52주 변동 폭
$5.51
$12.65
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
FOLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.76 | 2.14B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Why is Amicus Therapeutics Inc. stock going downMassive Profit Potential Picks - mustnews.co.kr
Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% HigherShould You Buy? - MarketBeat
What candlestick patterns are forming on Amicus Therapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Can trapped investors hope for a rebound in Amicus Therapeutics Inc.Free Daily Top Performing Stock Insights - Newser
How Efficient Is Amicus Therapeutics Inc. at Controlling Operating CostsFree ROI Boosting Trade Opportunity Calendar - Newser
Published on: 2025-08-08 22:45:59 - Newser
What institutional flow reveals about Amicus Therapeutics Inc.Predictive Model for Intraday Swing Forecast - Newser
Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wall Street Zen Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy - MarketBeat
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? - Yahoo Finance
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? - sharewise.com
Assetmark Inc. Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded at Wall Street Zen - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat
Amicus Therapeutics Inc. Rebound Backed by Sentiment ShiftFundamental + Technical Hybrid Stock Tips Shared - metal.it
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... By GuruFocus - Investing.com Canada
What are the latest earnings results for Amicus Therapeutics Inc.Invest in stocks with strong fundamentals - Jammu Links News
Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful portfolio management tools - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News
What catalysts could drive Amicus Therapeutics Inc. stock higher in 2025Phenomenal trading returns - Jammu Links News
When is Amicus Therapeutics Inc. stock expected to show significant growthDiscover stocks with massive upside potential - Jammu Links News
What are the technical indicators suggesting about Amicus Therapeutics Inc.Get daily expert analysis on top stocks - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
What drives Amicus Therapeutics Inc. stock priceMaximize your portfolio’s growth with expert tips - Jammu Links News
How does Amicus Therapeutics Inc. compare to its industry peersExceptional market performance - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stock outlookIntraday Price Forecast Using Volume Models - Newser
Should I hold or sell Amicus Therapeutics Inc. stock in 2025Unlock exclusive stock market insights - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Is it the right time to buy Amicus Therapeutics Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Amicus Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mesirow Financial Investment Management Inc. Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Victory Capital Management Inc. Purchases 82,691 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics' Q2 Performance: A Glimpse into Rare Disease Growth and Strategic Risks - AInvest
Amicus Therapeutics Surpasses $1B Target Revenues with DMX-200 License Agreement - AInvest
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha
FOLD Q2 Earnings Miss Mark, Revenues Beat On Higher Product Sales - Barchart.com
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript - Insider Monkey
What are analysts’ price targets for Amicus Therapeutics Inc. in the next 12 monthsDaily Trading Picks With High Returns - Jammu Links News
Envestnet Asset Management Inc. Has $1.52 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Reports Strong Growth Amid Strategic Advances - TipRanks
Amicus Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Amicus Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Drops 55.6% - AInvest
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):